Pulmonary arterial hypertension
ORPHA:182090CategoryAutosomal dominant, Not applicableAll ages
Эпидемиология12
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 2 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.6 | Spain | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.37 | Spain | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.5 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.24 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.09 | United States | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.07 | Czech Republic | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.24 | Czech Republic | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.55 | Switzerland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.35 | Switzerland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.72 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.2 | United Kingdom | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)